



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof

The Obesity Paradox in Infections and Implications for COVID-19

Carl J. Lavie, MD, FACC, Douglas B. Coursin, MD, FCCP, Micah T. Long, MD

PII: S0025-6196(21)00059-8

DOI: <https://doi.org/10.1016/j.mayocp.2021.01.014>

Reference: JMCP 3300

To appear in: *Mayo Clinic Proceedings*


Received Date: 14 January 2021

Accepted Date: 19 January 2021

Please cite this article as: Lavie CJ, Coursin DB, Long MT, The Obesity Paradox in Infections and Implications for COVID-19, *Mayo Clinic Proceedings* (2021), doi: <https://doi.org/10.1016/j.mayocp.2021.01.014>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Mayo Foundation for Medical Education and Research



The Obesity Paradox in Infections and Implications for COVID-19

Obesity has reached epidemic levels in the United States (US) and much of the Westernized world. (1,2) Recent statistics suggest that 75% of the US population is either overweight or obese, and 42% of Americans meet the current body mass index (BMI) criteria ($\text{BMI} \geq 30 \text{ kg/m}^2$) for obesity. Even more concerning is that 9% of US adults currently meet criteria for severe, Class III, or morbid obesity ($\text{BMI} \geq 40 \text{ kg/m}^2$). (1) Obesity places a “heavy” toll on the overall health of the population and on the healthcare system, (2) with a particularly adverse impact on cardiovascular (CV) health. Obesity worsens almost all CV disease (CVD) risk factors, exacerbating hypertension and dyslipidemia, and increasing insulin resistance. Obesity thus leads to metabolic syndrome and diabetes mellitus, and can cause chronic, low grade systemic inflammation. Not surprisingly, the development of almost all CVD is increased with obesity, including hypertension, coronary heart disease (CHD), heart failure (HF), and atrial fibrillation. In our current pandemic, patients with obesity who are infected with COVID-19 have endured increased respiratory symptoms, renal injury, coagulopathy, and thromboembolism, including pulmonary embolism (PE). (3) Additionally, obese individuals have many musculoskeletal abnormalities and have premature disabilities. (4)

Ironically, despite the increased health risks associated with obesity, patients with obesity and CVD have better short- and medium-term prognoses than do leaner patients with the same degree of CVD. (2,3,5) Termed the “Obesity Paradox,” these prognostic benefits have also been seen in end-stage renal disease, (6) and respiratory diseases, including chronic obstructive pulmonary disease (COPD), (7) as well as in PE. (8)

In this issue of the *Mayo Clinic Proceedings*, Grisholt and colleagues (9) report the mortality of patients who were hospitalized between 1/1/2011 and 9/30/2015 for non-COVID-related infections of varied sources: sepsis, pulmonary, urinary and skin. Data were drawn from the Central Denmark Region Clinical Information System, a comprehensive registry, of which 76,044 patients were admitted for infection and 35,406 also had height and weight data recorded within 30 days of hospitalization. In this subpopulation of patients with recent BMI, 25% were admitted with pneumonia, 12.5% with urinary tract infection and 11.2% with sepsis, with <10% admitted for skin and <5% with gastrointestinal infection.

For this study, the authors compared the risk of death in patients with a normal weight range (BMI 18.5-25 kg/m²) to patients who were underweight (BMI <18.5 kg/m²), overweight (BMI 25-30 kg/m²) and obese (BMI ≥30 kg/m²). The authors reported an obesity paradox, with lower mortality in hospitalized infected patients with obesity compared to normal weight individuals. Underweight patients, however, had the highest overall mortality rate [adjusted 90 mortality: aHR 1.75 (CI; 1.58 – 1.94)]. Compared to the US population, this Danish population exhibited a higher prevalence of smoking and had a much lower prevalence of obesity, thus also making the prevalence of moderate and severe obesity less likely, although this was not listed. The finding of considerably higher mortality in the underweight is not a major surprise, as this is seen in many other disease processes, likely due to comorbidities, like cancer or severe COPD, and less “reserve” to fight acute illnesses. However, compared with the normal BMI patients, those who were overweight and obese had 36% and 45% lower mortality, respectively.

The reasons for the obesity paradox in many conditions, including CVD, remain uncertain. Certainly, advanced HF is often associated with a state of cachexia and frailty, (10) so having higher weight and more muscle mass could itself be protective, or an associative marker of maintained vigor, but this

would not explain the obesity paradox seen in less severe HF and even stable CHD. As mentioned above, an obesity paradox has been noted in other conditions, including end-stage renal disease, COPD, and PE, among other conditions, (6-8) and the results of Grisholt and colleagues (9) are consistent with some other reports in hospitalized patients with pneumonia and other infections. It is crucial that future work evaluates potential medical management-based contributions to the obesity paradox, such as management of nutrition and fluid-balance. Further, interrogation of glycemic parameters in the obese versus non-obese is mandated, as current intermediate glucose goals (e.g. 130-180 mg/dL) approximate the baseline glucose of many patients with diabetes, but reflect a “glycemic gap” in those without, which may contribute to negative outcomes. (11)

For patients suffering in recent pandemics, including COVID-19 and H1N1, however, the obesity paradox has not applied. (12) Instead, the majority of data have suggested that obesity takes a particularly heavy toll on the prognosis in COVID-19 infection, including several reports from thousands of patients, (13-15) including those published in *Mayo Clinic Proceedings*. (3,16) COVID-19 infected patients with obesity exhibit more severe disease and are admitted to the intensive care unit (ICU) more frequently, with increased need for intubation and mechanical ventilation and a higher mortality. The reasons for the increased risk in obesity with COVID-19, as we reviewed previously, (3) include multiple co-morbidities, especially higher presence of CVD, but also that the adipocytes in the obese individual abundantly express ACE-2 receptors. The number of ACE-2 receptors in the adipose tissue of the obese is even greater than lung tissue, the site of coronavirus entry, thereby making fat a potential reservoir for the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) .

There are several other implications of interest regarding obesity in COVID-19. First, low serum 25-hydroxyvitamin D levels on hospital admission have been correlated with COVID-19 disease severity and

mortality, (17) and obese patients are known to have lower levels of vitamin D. (18) Vitamin D is essential to a host of immune functions, control of inflammation and modulation of the coagulation cascade. Vitamin D may be involved in decreasing the replication and survival of the SARS-CoV-2 through the induction of cathelicidins and defensins, major host anti-microbial defense proteins. Vitamin D is associated with maintenance of favorable ACE-2 levels and limitation of dysregulation in the renin-angiotensin system, which both limit viral entry and subsequent acute lung injury. (19) Further, with the recent release of various COVID-19 vaccines, there is concern that obese individuals may require larger doses or a third injection, based on the fact that influenza vaccinated obese adults are twice as likely to develop influenza and influenza-like illness compared with those of healthy weight adults, despite similar levels of immune response to the influenza vaccine. (20) Since the COVID-19 vaccines potentially could be less effective in adults with obesity, especially moderate and severe obesity, careful post-vaccination surveillance is needed. Thankfully, early data on COVID-19 vaccines suggest equal efficacy in patients with obesity, but longer-term follow up is required. (12)

Finally, a study in the *Proceedings* of 247 patients showed that higher levels of cardiorespiratory fitness (CRF) was associated with lower hospitalization rates in those infected with COVID-19. (21,22) This same study suggested fitness was more important than adiposity in determining the risk for COVID-19 hospitalizations. (23,24) Since physical activity and CRF may play a role in immunity against infections, (22) further studies are needed to assess phenotypic variation in these characteristics and the associated risk of negative outcomes, including hospitalizations, ICU admissions, need for mechanical ventilation, and mortality after infections, including COVID-19. Addressing the impact of physical activity and CRF in obese individuals would also be of interest in evaluating their response to COVID-19 vaccinations.

Clearly, obesity places a heavy toll on overall health and healthcare resource utilization, including in obese patients infected with SARS-CoV-2 virus. For other infections, added concern should be directed at more vigorous treatment for individuals in the normal weight range, and, even more so, for the underweight, where mortality is the highest.

Carl J. Lavie, MD, FACC^{1*}

Douglas B. Coursin, MD, FCCP²

Micah T. Long, MD³

¹Department of Cardiovascular Medicine, Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans, Louisiana

²Departments of Anesthesiology^{2,3} and Medicine², University of Wisconsin School of Medicine and Public Health, Madison, WI

*Corresponding Author:

Carl J. Lavie, MD, FACC

Address

Email: clavie@ochsner.org

References:

- 1) Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS data brief. 2020(360):1-8.
- 2) Lavie CJ, Laddu D, Arena R, Ortega FB, Alpert MA, Kushner RF. Healthy weight and obesity prevention: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(13):1506-1531.
- 3) Sanchis-Gomar F, Lavie CJ, Mehra MR, Henry BM, Lippi G. Obesity and outcomes in COVID-19: when an epidemic and pandemic collide. *Mayo Clin Proc* 2020;95(7):1445-1453.

- 4) Henriksson H, Henriksson P, Tynelius P, et al. Cardiorespiratory fitness, muscular strength, and obesity in adolescence and later chronic disability due to cardiovascular disease: a cohort study of 1 million men. *Eur Heart J* 2020;41(15):1503-1510.
- 5) Elagizi A, Carbone S, Lavie CJ, Mehra MR, Ventura HO. Implications of obesity across the heart failure continuum. *Prog Cardiovasc Dis* 2020;63(5):561-569.
- 6) Naderi N, Kleine CE, Park C, et al. Obesity paradox in advanced kidney disease: from bedside to the bench. *Prog Cardiovasc Dis* 2018;61(2):168-181.
- 7) Chittal P, Babu AS, Lavie CJ. Obesity paradox: does fat alter outcomes in chronic obstructive pulmonary disease? *COPD*. 2015 Feb;12(1):14-18.
- 8) Keller K, Hobohm L, Münzel T, et al. Survival benefit of obese patients with pulmonary embolism. *Mayo Clin Proc* 2019;94(10):1960-1973.
- 9) Gribsholt SB, Pedersen L, Richelsen B, Sørensen H, Thomsen R. Body mass index and 90-day mortality among 35,406 Danish patients hospitalized for infection. *Mayo Clin Proc*, In press.
- 10) Carbone S, Billingsley HE, Rodriguez-Miguel P, et al. Lean mass abnormalities in heart failure: the role of sarcopenia, sarcopenic obesity, and cachexia. *Curr Probl Cardiol* 2020;45(11):100417.
- 11) Bellaver P, Schaeffer AF, Dullius DP, Viana MV, Leitão CB, Rech TH. Association of multiple glycemic parameters at intensive care unit admission with mortality and clinical outcomes in critically ill patients. *Sci Rep* 2019;9(1):18498.
- 12) Vaccines and related biological products advisory committee meeting. Pfizer-BioNTech COVID-19 Vaccine FDA Briefing Document. Sponsor: Pfizer and BioNTech. December 10, 2020. Available at: <https://www.fda.gov/media/144245/download>. Downloaded January 1, 2021.
- 13) Goyal P, Ringel JB, Rajan M, et al. Obesity and COVID-19 in New York City: A Retrospective Cohort Study. *Ann Intern Med* 2020;173(10):855-858.

- 14) Anderson MR, Geleris J, Anderson DR, et al. Body mass index and risk for intubation or death in SARS-CoV-2 infection: a Retrospective Cohort Study. *Ann Intern Med* 2020;173(10):782-790.
- 15) Tartof SY, Qian L, Hong V, et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. *Ann Intern Med* 2020;173(10):773-781.
- 16) Sharma A, Garg A, Rout A, Lavie CJ. Association of obesity with more critical illness in COVID-19. *Mayo Clin Proc* 2020;95(9):2040-2042.
- 17) De Smet D, De Smet K, Herroelen P, Gryspeerdt S, Martens GA. Serum 25(OH)D level on hospital admission associated with COVID-19 stage and mortality. *Am J Clin Pathol* 2020 Nov 25:aqaa252. doi: 10.1093/ajcp/aqaa252. Epub ahead of print
- 18) de la Guía-Galipienso F, Martínez-Ferran M, Vallecillo N, Lavie CJ, Sanchis-Gomar F, Pareja-Galeano H. Vitamin D and cardiovascular health. *Clinical Nutrition*, <https://doi.org/10.1016/j.clnu.2020.12.025>
- 19) Santaolalla A, Beckmann K, Kibaru J, Josephs D, Van Hemelrijck M, Irshad S. Association between vitamin D and novel SARS-CoV-2 respiratory dysfunction: a scoping review of current evidence and its implication for COVID-19 pandemic. *Front Physiol* 2020;11:564387.
- 20) Neidich SD, Green WD, Rebeles J, et al. Increased risk of influenza among vaccinated adults who are obese. *Int J Obes (Lond)* 2017;41(9):1324-1330.
- 21) Brawner CA, Ehrman JK, Bole S et al. Inverse relationship of maximal exercise capacity to hospitalization secondary to coronavirus disease 2019. *Mayo Clin Proc* 2020; on-line first.
- 22) Lavie CJ, Sanchis-Gomar F, Arena R. Fit is it in COVID-19, future pandemics, and overall healthy living. *Mayo Clin Proc* 2020; on-line first.
- 23) Kerrigan D, Brawner C, Ehrman J, Keteyian S. Cardiorespiratory fitness attenuates the impact of risk factors associated with COVID-19 hospitalization. *Mayo Clin Proc*, In press.

- 24) Lavie CJ, Sanchis-Gomar F, Arena R. Fitness trumps fatness in COVID-19. *Mayo Clin Proc*, In press.